SCHEMBL20915035

SCHEMBL20915035

O=C(O)c1c[nH]nc1OCCC1CC1C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20915037 0.84 TSHR (0.38)
SCHEMBL23009908 0.79 KDM6B (0.40)
SCHEMBL23009919 0.77
SCHEMBL23009909 0.75
SCHEMBL20029798 0.73 CFTR (0.31)
SCHEMBL23009910 0.72 CCNE2 (0.31)
SCHEMBL20239848 0.69 DGAT1 (0.33)
SCHEMBL21815230 0.68 RARB (0.43)
SCHEMBL3263726 0.68 TSHR (0.42)
SCHEMBL21275065 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697774-B1 CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS VERTEX PHARMA (US) 2025-09-24 EP disclosed
CN-111757874-B Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2024-03-08 CN disclosed
CN-109803962-B Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions 弗特克斯药品有限公司 2022-04-29 CN disclosed
US-11155533-B2 Crystalline forms and compositions of CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-26 US disclosed
US-20200392109-A1 CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-12-17 US disclosed
CN-111757874-A Method for producing modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2020-10-09 CN disclosed
EP-3697774-A1 CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS Vertex Pharmaceuticals Incorporated (US) 2020-08-26 EP disclosed
US-10654829-B2 Crystalline forms and compositions of CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-19 US disclosed
WO-2019079760-A1 CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-04-25 WO disclosed
US-20190119253-A1 CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS VERTEX PHARAMCEUTICALS INCORPORATED (US) 2019-04-25 US disclosed